Malvidin is one of the most wide-spread anthocyanidins which exhibits potential antioxidant, anti-cancer and anti-inflammatory activities. Malvidin mainly exists as Malvidin-3-glucoside (Mv-3-glc) and Malvidin-3-galactoside (Mv-3-gal). The aim of the study was to investigate the two's anti-inflammatory effects on endothelial cells, as well as their synergistic effect. The results showed that Malvidin's glycoside could inhibit tumor necrosis factor-alpha (TNF-α)-induced increase in monocyte chemotactic protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) production both in the protein and messenger ribonucleic acid (mRNA) levels. The synergistic effect existed between Malvidin-3-glucoside and Malvidin-3-galactoside. In addition, they could inhibit degradation of IκBα and the nuclear translocation of p65, suggesting the anti-inflammation mechanism of Mv-3-glc and Mv-3-gal by the nuclear factor-kappa B (NF-κB) pathway. These results indicate the potential role of Malvidin's glycoside in preventing chronic inflammation in many diseases.